Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Phase 3Active Not RecruitingNCT06138613

Vanda Pharmaceuticals705 enrolled

Overview

An open label study to investigate the safety and efficacy of tradipitant in participants affected by motion sickness during travel

This is an open label study to investigate the efficacy and safety of tradipitant in motion sickness affected male and female participants during events historically known to cause motion sickness.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

705

Conditions

Motion Sickness

Interventions

TradipitantDRUG

Oral Capsule

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of Motion Sickness * Age 18-75 Exclusion Criteria: * Nausea-inducing disorder other than motion sickness * BMI \> 40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Locations (1)

Santa Monica Clinical Trials

Santa Monica, California, United States

Outcomes

Primary Outcomes

Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).

Safety will be monitored using clinical measures, vital signs, blood chemistry, hematology, urology, and ECGs.

Time frame: through study completion, approximately 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.